The numbers
Piramal Pharma Ltd’s stock touched an intraday low of Rs.134.8 on March 16, 2026, marking a notable decline of 32.81% over the last year. The company’s financial performance has raised concerns among investors, as evidenced by its recent rating of “Strong Sell.”
In the latest quarterly report, Piramal Pharma Ltd reported a Profit Before Tax loss of Rs.95.99 crore and a Profit After Tax loss of Rs.95.08 crore. These figures highlight the company’s ongoing financial struggles, with earnings per share (EPS) plummeting to Rs.-1.03 in the same period.
Additionally, the company carries a high Debt to EBITDA ratio of 3.83 times, which could further complicate its financial recovery. Despite these challenges, institutional investors hold a significant stake of 45.35% in Piramal Pharma Ltd, indicating a level of confidence from larger financial entities.
Piramal Pharma Ltd has been on a losing streak for four consecutive sessions, raising questions about its future performance in the stock market. The recent downturn has left many investors wary, as they assess the implications of the company’s financial health on its stock value.
Market analysts are closely monitoring the situation, as the combination of substantial losses and high debt levels could lead to further declines in share price. Observers are particularly interested in how the company plans to address its financial challenges moving forward.
As the market reacts to these developments, the outlook for Piramal Pharma remains uncertain. Investors are advised to stay informed about any upcoming announcements that may provide clarity on the company’s strategic direction.
Details remain unconfirmed regarding any potential measures the company may take to stabilize its financial position and restore investor confidence.
